Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FT836 · 1 trial · 6 indications
The number of participants experiencing ≥1 DLT will be reported.
The severity of DLTs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, v5.0).
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | CY/FLU followed by FT836 |
| Regimen B | EXPERIMENTAL | Standard-of-care (SOC) chemotherapy followed by FT836 |
| Regimen C | EXPERIMENTAL | FT836 combined with cetuximab |
| Regimen D | EXPERIMENTAL | CY/FLU followed by FT836 combined with cetuximab |
| Regimen D1 | EXPERIMENTAL | SOC chemotherapy followed by FT836 combined with cetuximab |
| Regimen E | EXPERIMENTAL | FT836 combined with trastuzumab |
| Regimen F | EXPERIMENTAL | CY/FLU followed by FT836 combined with trastuzumab |
| Regimen F1 | EXPERIMENTAL | SOC chemotherapy followed by FT836 combined with trastuzumab |
| Name | Type | Description |
|---|---|---|
| FT836 | DRUG | FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle. |
| Cetuximab | DRUG | Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion |
| Trastuzumab | DRUG | Trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion. |
Inclusion Criteria: * For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy. * Evidence of adequate organ function as determined by all of the following: * Absolute neutrophil count (ANC) \>100...
Top 20 of 79 competitors
FT836 is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer. It is currently in Phase 1 clinical development, with a trial evaluating it alone or with chemotherapy and/or monoclonal antibodies in participants with advanced solid tumors, including Non-Small Cell Lung Cancer.
FT836 targets MICA/B, a protein involved in the immune response to tumors. By targeting MICA/B, FT836 is designed to modulate this pathway, potentially enhancing the body's ability to fight cancer cells. It is being investigated as a therapeutic option for advanced solid tumors.
FT836 is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol FATE. The company is conducting clinical research to evaluate the safety and efficacy of FT836 in patients with advanced solid tumors.
FT836 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
FT836 is being studied in a Phase 1 clinical trial with the identifier NCT07216105. This trial is titled 'FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors' and is currently recruiting participants in the United States.
No, FT836 is a unique investigational drug and is not known to be the same as any other approved or investigational medication. It is a small molecule developed by Fate Therapeutics, Inc., and is being studied specifically for its potential role in treating advanced solid tumors.